I'm LongbridgeAI, I can summarize articles.Sinobioway Medicine announced that its holding subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., may trigger other risk warnings due to the suspension of production and sales. According to the relevant regulations of the Shenzhen Stock Exchange, if the company's production and operation are severely affected and it is expected to be unable to resume normal operations within three months, risk warnings will be implemented. This event has a significant impact on the production and operation of Sinobioway Medicine
According to the Zhitong Finance APP, Sinobioway Medicine (002581.SZ) announced a stock price fluctuation, stating that its controlling subsidiary Tianjin Sinobioway Biomedical Co., Ltd. (referred to as "Tianjin Sinobioway") was subjected to risk control measures of suspending production and sales on April 22, 2025. According to Article 9.8.1 (5) of the "Shenzhen Stock Exchange Stock Listing Rules" (2025 revision): If the company's production and operation activities are severely affected and are expected to not return to normal within three months, the company's stock will be subject to other risk warnings. Tianjin Sinobioway is an important subsidiary of the company, and the aforementioned event has a significant impact on the company's production and operations. If Tianjin Sinobioway is expected to be unable to resume production within three months, the company may trigger other risk warnings